The current stock price of APRI is 0.22 null. In the past month the price increased by 15.79%. In the past year, price decreased by -90.52%.
Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT '. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT' drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.
Apricus Biosciences Inc
11975 EL CAMINO REAL SUITE 300
SAN DIEGO CA 92130
CEO: Richard W. Pascoe
Phone: 858-222-8041
Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT '. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT' drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.
The current stock price of APRI is 0.22 null. The price decreased by -4.35% in the last trading session.
APRI does not pay a dividend.
APRI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on APRI.
ChartMill assigns a technical rating of 1 / 10 to APRI. When comparing the yearly performance of all stocks, APRI is a bad performer in the overall market: 98.39% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to APRI. Both the profitability and financial health of APRI have multiple concerns.
Over the last trailing twelve months APRI reported a non-GAAP Earnings per Share(EPS) of -0.52. The EPS increased by 13.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -176.71% | ||
| ROE | -239.05% | ||
| Debt/Equity | 0 |